NTLA R&D to Revenue
Intellia Therapeutics Inc · R&D to Revenue
NTLA R&D to Revenue
Latest reported1078.40%period ending
NTLA Quarterly R&D/Revenue (0.00% → 1078.40%)
Latest values, visible window
High-resolution chart · PNG
NTLA r&d to revenue history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D to Revenue |
|---|---|
| 1,078.4045% | |
| 536.5298% | |
| 385.1588% | |
| 687.4692% | |
| 681.1864% | |
| 652.114% | |
| 907.853% | |
| 1,354.1872% | |
| 1,604.2547% | |
| 377.8642% | |
| -5,684.9765% | |
| 948.0987% | |
| 847.9918% | |
| 770.395% | |
| 737.0073% | |
| 728.5617% | |
| 642.9009% | |
| 1,182.8564% | |
| 553.6098% | |
| 839.6169% | |
| 898.9924% | |
| 609.4026% | |
| 579.6967% | |
| 178.9199% | |
| 232.2511% | |
| 268.2719% | |
| 290.1518% | |
| 259.1654% | |
| 228.998% | |
| 227.2501% | |
| 252.7665% | |
| 313.6744% | |
| 305.6793% | |
| 301.1514% | |
| 317.4865% | |
| 238.9094% | |
| 263.0556% | |
| 216.1062% | |
| 201.3684% | |
| 161.45% | |
| 176.486% | |
| 294.0349% | |
| 258.417% | |
| 204.8578% | |
| 142.7741% | |
| 106.6096% | |
| 0% | |
| 0% |